Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × CPG-oligonucleotide × Thoracic × Clear all
NCT04952272 2024-06-26

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 1 Recruiting
50 enrolled
GastrointestinalThoracic

Carcinoma, Hepatocellular, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡